Antidiabetic combination therapy and cardiovascular outcomes: An evidence-based approach

doi:10.4239/wjd.v16.i4.102390

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (0)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

HTML

Figures (1-3)

Tables (1-2)

Sum=0

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=0

Apr 15, 2025 (publication date) through Feb 28, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Diabetes. Apr 15, 2025; 16(4): 102390
Published online Apr 15, 2025. doi: 10.4239/wjd.v16.i4.102390

Full Size Figure Download Figure

Figure 1 The putative mechanisms for cardiovascular protection associated with the use of glucagon-like insulinotropic peptide-1 receptor agonists. GLP-1: Glucagon-like insulinotropic peptide-1.

Citation: Ganakumar V, Fernandez CJ, Pappachan JM. Antidiabetic combination therapy and cardiovascular outcomes: An evidence-based approach. World J Diabetes 2025; 16(4): 102390
URL: https://www.wjgnet.com/1948-9358/full/v16/i4/102390.htm
DOI: https://dx.doi.org/10.4239/wjd.v16.i4.102390